Weight loss injections on TikTok: what GLP-1 videos get wrong

What's this video probably claiming?

Based on the hashtags and caption, this video is almost certainly doing one of a few things: celebrating weight loss results from semaglutide or tirzepatide, comparing the two drugs, or walking through how these injections work for fat loss. Videos tagged with both drug names tend to pitch one of three narratives: these are miracle shots, tirzepatide beats semaglutide hands down, or anyone can get them easily. The 21.6K views suggest the content hit an audience that's already curious or currently using one of these medications. What rarely shows up in these videos is the part about how these drugs work, what the clinical trial populations actually looked like, or what happens when you stop taking them. That context isn't viral. But it's the part that matters most if you're deciding whether to start.

What does the science actually show?

The clinical data on both drugs is genuinely strong, which makes the exaggeration in social media content more frustrating than usual. In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), tirzepatide at 15mg weekly produced mean body weight reduction of 20.9% over 72 weeks in adults with obesity. For semaglutide 2.4mg weekly, the STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% mean body weight reduction over 68 weeks. These are real, large differences from placebo. But both trials enrolled people who combined the drug with reduced-calorie diets and increased physical activity. The drugs were not tested in isolation. Additionally, the STEP 4 trial (Rubino et al., 2021, JAMA) showed that participants who discontinued semaglutide regained two-thirds of their prior weight loss within one year. That finding almost never makes it into TikTok videos.

Where does the social media noise diverge from clinical reality?

The biggest gap between TikTok and the clinic is the framing of these medications as permanent fixes rather than chronic treatments. Most viral content shows dramatic before-and-after results without mentioning that these effects depend on continuous use. There's also a persistent conflation of compounded semaglutide or tirzepatide with the FDA-approved brand-name products. Compounded versions are not therapeutically equivalent to Wegovy, Ozempic, Mounjaro, or Zepbound. The FDA has stated this explicitly. Compounded drugs are not FDA-approved and have not gone through the same efficacy and safety review. Videos also tend to skip the side effect profile: nausea, vomiting, and diarrhea affect a substantial portion of users, and the SURMOUNT-1 data showed serious adverse events in roughly 6% of the tirzepatide group. Pancreatitis, while rare, is also a documented concern requiring monitoring.

What should you actually know?

If you're considering either of these medications, a few things are worth understanding before you watch another TikTok about them. First, these are prescription drugs that require medical evaluation, not products you self-prescribe based on a creator's transformation story. Second, the weight loss data is real but comes with conditions: both drugs work best alongside dietary changes and activity, and effects diminish when the medication stops. Third, individual response varies considerably. Not everyone loses 15-20% of body weight. Some people lose significantly less, and gastrointestinal side effects cause a meaningful number of patients to reduce their dose or discontinue. Fourth, cost and access remain real barriers. Without insurance coverage, monthly costs for brand-name options can exceed $1,000. Anyone telling you this is straightforward is skipping the complicated parts on purpose.